Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 1, 2016, Pages 23-31

  Carbone, Laura J ^a   Angus, Peter W ^b   Yeomans, Neville D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

DPP 4I; GLP 1 RA; Incretin system; NAFLD; NASH; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOCHEMICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COMORBIDITY; DRUG EFFICACY; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; AGONISTS; BIBLIOGRAPHIC DATABASE; BLOOD; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; NON-ALCOHOLIC FATTY LIVER DISEASE;

ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; COMORBIDITY; DATABASES, BIBLIOGRAPHIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INCRETINS; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

EID: 84956914555     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13026     Document Type: Article

References (48)

1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-31.
2. Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract. Res. Clin. Endocrinol. Metab. 2013; 27: 195-208.
3. Ratziu V, Bellentani S, Cortez-Pinto H et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010; 53: 372-84.
4. Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-Analysis. Int. J. Endocrinol. 2013; 2013: 124958. doi: 10.1155/2013/124958.
5. Younossi Z, Stepanova M, Afendy M et al. Changes in the prevalence of the most common causes of chronic liver disease in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 2011; 9: 524-30.
6. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
7. Amarapurkar D, Hashimoto E, Lesmana L et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J. Gastroenterol. Hepatol. 2007; 22: 788-93.
8. Charlton MR, Burns JM, Pedersen RA et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-53.
9. Samson SL, Bajaj M. Potential of incretin-based therapies for non-alcoholic fatty liver disease. J. Diabetes Complications 2013; 27: 401-6.
10. Drucker D, Nauck M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
11. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3: 153-65.
12. Chaudhuri A, Ghanim H, Vora M et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 2012; 97: 198-207.
13. Makdissi A, Ghanim H, Vora M et al. Sitagliptin exerts an antinflammatory action. J. Clin. Endocrinol. Metab. 2012; 97: 3333-41.
14. Larter C, Chitturi S, Heydet D et al. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J. Gastroenterol. Hepatol. 2010; 25: 672-90.
15. Utzschneider K, Kahn S. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2006; 91: 4753-61.
16. Blaslov K, Bulum T, Zibar K et al. Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J. Gastroenterol. 2014; 20: 7356-65.
17. Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005; 115: 1343-51.
18. Farrell G, van Rooyen D, Gan L et al. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 2012; 6: 149-71.
19. Bernsmeier C, Meyer-Gerspach A, Blaser L et al. Glucose-induced glucagon-like peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One 2014; 9: e87488.
20. Svegliati-Baroni G, Saccomanno S, Rychlicki C et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int. 2011; 31: 1285-97.
21. Miyazaki M, Kato M, Tanaka K et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol. Med. Rep. 2012; 5: 729-33.
22. Ding X, Saxena N, Lin S et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Hepatology 2006; 43: 173-81.
23. Mells J, Fu P, Sharma S et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G225-35.
24. Akaslan SB, Degertekin CK, Yilmaz G et al. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. Metab. Syndr. Relat. Disord. 2013; 11: 243-50.
25. Trevaskis J, Griffin P, Wittmer C et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G762-72.
26. Gupta N, Mells J, Dunham R et al. Glucagon-like peptide-1 receptor (GLP-1R) is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signalling pathway. Hepatology 2010; 51: 1584-92.
27. Farrell G, Chitturi S, Lau G et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J. Gastroenterol. Hepatol. 2007; 22: 775-7.
28. Chalasani N, Younossi Z, Lavine J et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609.
29. Moher D, Liberati A, Tetzlaff J et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097.
30. Effective Public Health Practice Project. Quality assessment tool for quantitative studies, Canada, 2007.
31. Eguchi Y, Kitajima Y, Hyogo H et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol. Res. 2015; 45: 269-78.
32. Cuthbertson D, Irwin A, Gardner C et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 2012; 7: e50117.
33. Ohki T, Isogawa A, Iwamoto M et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Scientific World Journal 2012; 2012: 496453.
34. Iwasaki T, Yoneda M, Inamori M et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011; 58: 2103-5.
35. Musso G, Gambino R, Cassader M et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 2011; 43: 617-49.
36. Seko Y, Sumida Y, Tanaka S et al. Serum alanine aminotransferase predicts the histological course of nonalcoholic steatohepatitis in Japanese patients. Hepatol. Res. 2014. doi: 10.1111/hepr.12456. [Epub ahead of print].
37. Samson S, Sathyanaryana P, Jogi M et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011; 54: 3093-100.
38. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21: 1539-58.
39. Kenny PR, Brady DE, Torres DM et al. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am. J. Gastroenterol. 2010; 105: 2707-9.
40. Yilmaz Y, Yonal O, Deyneli O et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol. Belg. 2012; 75: 240-4.
41. Kanazawa I, Tanaka K, Sugimoto T. DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus. Med. Sci. Monit. 2014; 20: 1662-7.
42. Fan H, Pan Q, Xu Y et al. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq. Bras. Endocrinol. Metabol. 2013; 57: 702-8.
43. Sathyanaryana P, Jogi M, Muthupillai R et al. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity 2011; 19: 2310-5.
44. Song X-X, Jiang T, Kang K et al. Efficacy of sitagliptin combined with metformin in the initial treatment of type 2 diabetes with non-alcoholic fatty liver. Chin. J. New Drugs 2014; 23: 215-8, 240.
45. Hopewell S, Loudon K, Clarke M et al. Publication Bias in Clinical Trials due to Statistical Significance or Direction of Trial Results. United Kingdom: The Cochrane Collaboration, 2009.
46. Borenstein M, Hedges L, Higgins J et al. Introduction to Meta-analysis. United Kingdom: John Wiley & Sons, Ltd, 2009; 277-92.
47. Musso G, Cassader M, Rosina F et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885-904.
48. Prins J. Incretin mimetics and enhancers: mechanisms of action. Aust. Prescr. 2008; 31: 102-4.